Rubius Therapeutics Inc. buy me8
Start price
04.09.22
/
0%
€1.14
Target price
04.09.23
-
Performance (%)
-92.50%
End price
05.09.23
-
Summary
This prediction is currently being closed. Massive losses of -92.50% have been the result for the BUY prediction by me8. This prediction was marked as speculative and is excluded from me8's performance statistics.Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Rubius Therapeutics Inc. | - | - | - |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% |
According to me8 what are the pros and cons of Rubius Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Very capable Management
Good culture
Top 10 in its market
Cons
Sustainability is little important
Higher risks for its business
Comments by me8 for this prediction
In the thread Rubius Therapeutics Inc. diskutieren
Buy Rubius Therapeutics Inc.
In the thread Trading Rubius Therapeutics Inc.
Die von me8 gewählte maximale Laufzeit wurde überschritten
Stopped prediction by me8 for Rubius Therapeutics Inc.
Rubius Therapeutics Inc.
Start price
Target price
Perf. (%)
€8.20
14.12.20
14.12.20
€11.00
14.12.21
14.12.21
15.85%
29.01.21
29.01.21
Could be worthwhile Investment >10% per year
Very capable Management
Good culture
Sustainability is little important
